Q1 Earnings Estimate for ANIP Issued By Leerink Partnrs

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for ANI Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 9th. Leerink Partnrs analyst F. Khurshid anticipates that the specialty pharmaceutical company will post earnings of $0.91 per share for the quarter. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for ANI Pharmaceuticals' Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.23 EPS, Q4 2025 earnings at $1.50 EPS, FY2025 earnings at $4.90 EPS and FY2026 earnings at $5.43 EPS.

A number of other equities analysts have also issued reports on ANIP. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. Guggenheim restated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.

ANI Pharmaceuticals Trading Up 0.1 %

Shares of ANI Pharmaceuticals stock traded up $0.06 during trading hours on Friday, hitting $69.61. The company's stock had a trading volume of 111,579 shares, compared to its average volume of 268,647. The business has a fifty day moving average of $62.71 and a 200 day moving average of $59.22. The company has a market capitalization of $1.52 billion, a PE ratio of -126.56 and a beta of 0.49. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $70.79.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ANIP. US Bancorp DE raised its holdings in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV raised its stake in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after acquiring an additional 600 shares during the last quarter. GAMMA Investing LLC lifted its holdings in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the period. KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals during the fourth quarter worth $166,000. Finally, Rafferty Asset Management LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter valued at $200,000. Institutional investors own 76.05% of the company's stock.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares in the company, valued at $5,526,799.20. The trade was a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,200 shares of company stock worth $197,792 in the last 90 days. 12.70% of the stock is owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.